Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients

Experimental Hematology

Volumn 39, Issue 9, 2011, Pages 892-896

  Crocchiolo, R ^a   Castagna, L ^a   El Cheikh, J ^a   Helvig, A ^a   Furst S ^a   Faucher, C ^a   Vazquez, A ^a   Granata, A ^a   Coso, D ^a   Bouabdallah, R ^a   Blaise, D ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; RITUXIMAB; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE COMPARISON; FOLLICULAR LYMPHOMA; HUMAN; IN VIVO STUDY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; RETROSPECTIVE STUDY; T CELL DEPLETION; TREATMENT DURATION; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA; WHOLE BODY RADIATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LYMPHOCYTE DEPLETION; LYMPHOMA; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES;

EID: 80051470064     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.06.006     Document Type: Article

References (27)

1. Socié G., Blazar B.R. Acute graft-versus-host disease: from the bench to the bedside. Blood 2009, 114:4327-4336.
2. Lee S.J. New approaches for preventing and treating chronic graft-versus-host disease. Blood 2005, 105:4200-4206.
3. Shimabukuro-Vornhagen A., Hallek M.J., Storb R.F., von Bergwelt-Baildon M.S. The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009, 114:4919-4927.
4. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006, 12:560-565.
5. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 98:2942-2947.
6. Schultz K.R., Paquet J., Bader S., HayGlass K.T. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 1995, 16:289-295.
7. Greinix H.T., Pohlreich D., Kouba M., et al. Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008, 14:208-219.
8. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009, 113:3865-3874.
9. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007, 13:6107-6114.
10. Iori A.P., Torelli G.F., De Propris M.S., et al. B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation. Transplantation 2008, 85:386-390.
11. Michonneau D., Peffault de Latour R., Porcher R., et al. Influence of bone marrow graft B lymphocyte subsets on outcome after HLA-identical sibling transplants. Br J Haematol 2009, 145:107-114.
12. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008, 111:5530-5536.
13. Arai S., Sahaf B., Jones C., et al. Prophylactic rituximab after reduced intensity conditioning transplantation results in low chronic GvHD [abstract]. Blood 2008, 112. Abstract 466.
14. Ratanatharathorn V., Logan B., Wang D., et al. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 2009, 145:816-824.
15. Canninga-van Dijk M.R., van der Straaten H.M., Fijnheer R., Sanders C.J., van den Tweel J.G., Verdonck L.F. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004, 104:2603-2606.
16. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006, 108:756-762.
17. Zaja F., Bacigalupo A., Patriarca F., et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007, 40:273-277.
18. Kim S.J., Lee J.W., Jung C.W., et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica 2010, 95:1935-1942.
19. Mohty M., Marchetti N., El-Cheikh J., Faucher C., Fürst S., Blaise D. Rituximab as salvage therapy for refractory chronic GvHD. Bone Marrow Transplant 2008, 41:909-911.
20. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007, 21:1387-1394.
21. Berinstein N.L., Grillo-López A.J., White C.A., et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998, 9:995-1001.
22. Pillai A.B., George T.I., Dutt S., Teo P., Strober S. Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol 2007, 178:6242-6251.
23. Pillai A.B., George T.I., Dutt S., Strober S. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood 2009, 113:4458-4467.
24. Glass B., Hasenkamp J., Görlitz A., et al. Rituximab for graft-versus-host-disease prophylaxis after allogeneic stem cell transplantation given as treatment of high risk relapse of aggressive lymphoma: results of a randomized phase 2 study [abstract]. Blood 2008, 112. Abstract 1974.
25. Christopeit M., Schütte V., Theurich S., Weber T., Grothe W., Behre G. Rituximab reduces the incidence of acute graft-versus-host disease. Blood 2009, 113:3130-3131.
26. van Dorp S., Pietersma F., Wölfl M., et al. Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD. Biol Blood Marrow Transplant 2009, 15:671-678.
27. Bornhaeuser M., Schwerdtfeger R., Kroschinsky F., et al. Pretreatment with rituximab reduces the incidence of chronic graft-versus-host disease after allogeneic stem cell transplantation in patients with B cell lymphoma [abstract]. Blood 2004, 104. Abstract 1233.